The Yale School of Public Health Leaders in Public Health series presents
Dean Megan Ranney and Dr. Moupali Das, MD, MPH, Vice President, Clinical Development, HIV Prevention and Virology Pediatrics, Gilead Sciences:
“Creating Breakthrough Science and Inclusive Clinical Trials.”
Since joining Gilead Sciences, Dr. Das has leveraged her clinical HIV and infectious disease expertise, clinical trial design and epidemiology skills, and passion for coaching and mentoring to build and lead high-performing cross-functional teams in HIV treatment and prevention.
She has led the PURPOSE program, which is evaluating long-acting lenacapavir for HIV prevention, and HIV Prevention Clinical Development with passion and empathy, revolutionizing how we develop drugs, innovating in the science and health equity, and laying the groundwork for global access. Her research prior to joining Gilead included the development of a novel population-based indicator, community viral load (CVL), to evaluate the impact of treatment as prevention. Her CVL research was the basis for measuring CVL and using viral suppression to evaluate the effectiveness of President Barack Obama’s National HIV/AIDS Strategy.